Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes

JAMA Neurology

Volumn 72, Issue 10, 2015, Pages 1183-1190

  Schreiber, Stefanie ^a   Landau, Susan M ^a,d   Fero, Allison ^a,d   Schreiber, Frank ^a,b,c,e   Jagust, William J ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; CANADA; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERRATER RELIABILITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; UNITED STATES; COMPLICATION; METABOLISM; MIDDLE AGED; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84944104375     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1633     Document Type: Article

References (38)

1. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aß42 in humans. Ann Neurol. 2006;59(3):512-519.
2. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.
3. Jagust WJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.
4. Landau SM, Lu M, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of ß-amyloid. Ann Neurol. 2013;74(6):826-836.
5. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
6. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
7. Doraiswamy PM, Sperling RA, Coleman RE, et al; AV45-A11 Study Group. Amyloid-ß assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636-1644.
8. Ewers M, Insel P, Jagust WJ, et al; Alzheimer's Disease Neuroimaging Initiative (ADNI). CSF biomarker and PIB-PET-derived ß-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012;22(9):1993-2004.
9. Jack CR Jr, Wiste HJ, Vemuri P, et al; Alzheimer's Disease Neuroimaging Initiative. Brain ß-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133(11):3336-3348.
10. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76(12):1085-1090.
11. Landau SM, Mintun MA, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586.
12. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73(10):754-760.
13. Ong KT, Villemagne VL, Bahar-Fuchs A, et al. aß imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431-436.
14. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
15. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557-568.
16. Doraiswamy PM, Sperling RA, Johnson K, et al; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051.
17. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40(1):104-114.
18. Petersen R. Conceptual overview. In: Petersen RC, ed. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York, NY: Oxford University Press; 2003:1-14.
19. Wechsler D. Wechsler Memory Scale-Revised Manual. San Antonio, TX: Psychological Corp; 1987.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
21. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
22. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-238.
23. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
24. Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.
25. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218.
26. Zwan MD, Ossenkoppele R, Tolboom N, et al. Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55(8):1305-1307.
27. Thurfjell L, Lilja J, Lundqvist R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55(10):1623-1628.
28. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1(8-9):371-380.
29. Schöll M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229-236.
30. Mattsson N, Insel PS, Donohue M, et al; Alzheimer's Disease Neuroimaging Initiative. Independent information from cerebrospinal fluid amyloid-ß and florbetapir imaging in Alzheimer's disease. Brain. 2015;138(pt 3):772-783.
31. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169-1171.
32. Langbaum JB, Fleisher AS, Chen K, et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013;9(7):371-381.
33. Cohen AD, Mowrey W, Weissfeld LA, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207-215.
34. Clark CM, Pontecorvo MJ, Beach TG, et al; AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-ß plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678.
35. Zwan M, Van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis. 2014;41(3):801-807.
36. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aß and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181-192.
37. Grimmer T, Wutz C, Drzezga A, et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2013;10(1):82-85.
38. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with ß-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74(6):905-913.